Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Myovant Sciences’ uterine fibroids combo therapy meets main goal in study

Myovant Sciences’ combination therapy met the main goal of a late-stage study testing the treatment in women with uterine fibroids.

Read More »

Positive Data in 3 Studies for 2 AstraZeneca Drugs

AstraZeneca released positive data from two clinical trials of roxadustat in anemia and of the company’s study of Lynparza in ovarian cancer.

Read More »

China approves AstraZeneca, FibroGen anemia drug

China became the first country to approve a new anemia drug from AstraZeneca and FibroGen, well before decisions by regulators in the United States or Europe.

Read More »

Alexion to obtain Syntimmune

Alexion Pharmaceuticals is acquiring Syntimmune, a company working to produce antibody therapeutics that focus on the neonatal Fc receptor (FcRn), for a total value of up to $1.2 billion.

Read More »

Astellas Pushes Outside of Oncology, Releases Positive Results in Anemia Trials

Tokyo-based Astellas Pharma announced that the company’s roxadustat met the primary endpoints in the Phase III ALPS clinical trial in chronic kidney disease patients with anemia not on dialysis.

Read More »

AstraZeneca plots China robot offensive to counter price cuts

With smart cancer diagnostics, one-stop-shop diabetes kits and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca aims to move from simply supplying drugs to become a broad healthcare provider in China.

Read More »

GBT’s sickle cell disease drug meets trial goal

Global Blood Therapeutics’ sickle cell disease treatment met the main goal of a late-stage trial, but there is scepticism over whether the drug would get an accelerated review from health regulators.

Read More »

Anemia Patients Benefit from bluebird’s LentiGlobin Gene Therapy, Trial Data Shows

Cambridge, Mass.-based bluebird bio’s LentiGlobin gene therapy is increasing hemoglobin levels in anemia patients battling sickle cell disease and beta thalassemia, which reduces the need for blood transfusions in those patients.

Read More »

AMAG Pharmaceuticals Divests Cord Blood Registry for $530 Million

Waltham, Mass.-based AMAG Pharmaceuticals will secure $530 million in cash as the company divests Cord Blood Registry to GI Partners, a private equity investment firm.

Read More »

Rigel’s Tavalisse Fails Kidney Disease Trial

As Rigel Pharmaceuticals awaits a regulatory decision for Tavalisse (fostamatinib) for a platelet disorder, the company reported a developmental setback for the therapy in another clinical trial.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom